rethinkPeptides Search
Menu
Research citation

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.

Frontiers in endocrinology, 16, 1716247

Citation

Kolodziej, Maciej; Opalinska, Marta; Mikolajczak, Renata; Hubalewska-Dydejczyk, Alicja; Dedecjus, Marek; Kowalska, Aldona; Saracyn, Marek; Garnuszek, Piotr; Cieszykowska, Izabela; Januszkiewicz-Caulier, Joanna; Dlugosinska, Joanna; Durma, Adam Daniel; Jozwik-Plebanek, Katarzyna; Mroz, Adrianna; Janiak, Katarzyna; Gasior-Perczak, Danuta; Trofimiuk-Muldner, Malgorzata; Sowa-Staszczak, Anna; Braziewicz, Janusz; Lenda-Tracz, Wioletta; Kacperski, Krzysztof; Budzynska, Anna; Kubik, Agata; Pastusiak, Patrycja; Chalewska, Wioletta; Borkowska, Anna; Cegla, Paulina; Walecka-Mazur, Agata; Szczodry, Artur; Kaminski, Grzegorz. (2025). Dosimetry-guided peptide receptor radionuclide therapy in neuroendocrine tumors: interim safety analysis of the DUONEN trial.. Frontiers in endocrinology, 16, 1716247. https://doi.org/10.3389/fendo.2025.1716247